Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire March 22, 2021

Aeterna Zentaris (TSX:AEZS) announces license agreement and research contract

John Ballem  March 15, 2021

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19

GlobeNewswire March 15, 2021

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion - Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism

GlobeNewswire March 11, 2021

Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire February 24, 2021

Aeterna Zentaris (TSX:AEZS) announces closing of $29.7 million bought deal offering of common shares

Trevor Abes  February 19, 2021

Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares

GlobeNewswire February 19, 2021

Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million

GlobeNewswire February 16, 2021

Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares

GlobeNewswire February 16, 2021

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg

GlobeNewswire February 2, 2021

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

GlobeNewswire January 28, 2021

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire January 26, 2021

Aeterna Zentaris to Present at NobleCon17

GlobeNewswire January 15, 2021

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

GlobeNewswire January 5, 2021

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

GlobeNewswire December 7, 2020

The Biotech Breakthrough Transforming Mental Health

Livemoney December 1, 2020

Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

GlobeNewswire November 16, 2020

Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 6, 2020

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc. - AEZS

PR Newswire October 9, 2020

Aeterna Zentaris Provides Corporate Update

GlobeNewswire September 16, 2020